Oric Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing cancer therapies designed to overcome resistance mechanisms. The company's pipeline centers on small molecule inhibitors targeting specific oncogenic drivers and resistance pathways. Lead candidate ORIC-114 is a brain-penetrant EGFR inhibitor in Phase 1b development, targeting exon 20 insertion mutations in lung cancer. ORIC-944, an allosteric inhibitor of polycomb repressive complex 2, is being evaluated in Phase 1b studies for prostate cancer. Additional programs include ORIC-533, a CD73 inhibitor in development for multiple myeloma and other indications, and ORIC-613, a small molecule candidate addressing innate resistance mechanisms in breast cancer.

The company has established collaboration agreements with major pharmaceutical partners to advance clinical development. Pfizer is collaborating on a potential Phase 2 study of ORIC-533 in multiple myeloma. Bayer and Johnson & Johnson have entered clinical trial collaboration and supply agreements to evaluate ORIC-944 in combination with their respective AR inhibitor programs. These partnerships indicate validation of ORIC's approach and provide clinical development funding and resources.

ORIC operates as a private research organization with 106 full-time employees and is headquartered in South San Francisco, California. The company was incorporated in Delaware in 2014 and is listed on Nasdaq.